×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Cure Connections

Before Dr. Eskander turns to the future treatment of ovarian cancer, participants consider how the treatment journey can affect caregivers.
A breakdown of the support networks patients can build and rely on as they receive treatment for ovarian cancer.
Considerations for maintaining mental and emotional well-being while going through a diagnosis of and treatment for ovarian cancer.
Doña Harman shares how stigma surrounding cancer affected the reactions of some around her, while others offered their support.
More

Cure Expert Connections

The importance of support networks and a multidisciplinary team when managing advanced-stage renal cancer.
A discussion regarding the significance of dose modification to mitigate toxicity burden.
Steven Gallant, a stage 4 renal cell cancer survivor, discusses how he managed the toxicities of cabozantinib frontline therapy.
A discussion regarding the frontline treatment options for aggressive renal cell cancer, and the factors considered in choosing the appropriate therapy.
More

Cure TV

Nancy Cohen
To combat the stigma around mental health care for patients with lung cancer, survivor Nancy Cohen shares her own treatment story and why she feels it's important to include mental health care during cancer treatment.
Dr. Hossein Borghaei
Hossein Borghaei, DO, MS, of Fox Chase Cancer Center, discusses emerging treatment options for patients with lung cancer.
Dr. Brian I. Rini
When asked about the future of renal cell carcinoma (RCC) treatment, one expert is hopeful about the current search, but notes that more work is needed to find a reliable biomarker for use in patients with the most common kind of kidney cancer.
SPONSORED CONTENT
Optune caregivers offer advice and support to fellow caregivers.
More

Cure Speaking Out

More
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×